Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 4;219(10):e202006196. doi: 10.1083/jcb.202006196

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Ozawa et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Arp2/3 complex at junctions and its interaction with WRC and F-actin. (A and B) Coimmunostaining for p34/ARPC2 (p34), Abi1 and actin (top), and p34/ARPC2 and E-cadherin (bottom) in wild-type (A) or αEcat KO (B) Caco2 cells. J, the position of junction. Marginal or marginal plus submarginal cells are shown throughout this figure. (C) Coimmunostaining for Abi1, E-cadherin, and actin in wild-type or αE-cat KO Caco2 cells, which were incubated with 10 µM latrunculin A for 60 min. The boxed regions are enlarged. The overlapping ratios of these molecules were quantified. Magenta arrows, Abi1–actin coclusters; white arrows, Abi1–E-cadherin–actin coclusters; green arrows, E-cadherin fragments that do not overlap with other molecules. (D) Effect of p34/ARPC2 siRNA treatment on actin assembly. Arrows point to actin-positive structures that are not closely associated with the junctions. Magnification is shown in the partly enlarged images. Scale bars, 10 µm.